Among the 43 evaluable patients treated with sevabertinib, the confirmed objective response rate was 72.1%.

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), ...

Explore how cutting-edge agents like alpelisib, capivasertib, MEK and ERK inhibitors, and JAK inhibitors are reshaping the ...

Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of ...

Vepdegestrant may prolong progression-free survival in ESR1-mutated, ER-positive, HER2-negative advanced breast cancer, ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...

CHICAGO >> Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance ...

Dr. Sarah Sammons discusses side effects associated with RLY-2608, and how it effects patients with HR-positive, HER2-negative advanced breast cancer.

Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer ...

AstraZeneca has produced some fresh data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...